drugset / Trial / NCT03095079

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

NCT03095079

Phase 2 Unknown 70 enrolled Peking University Cancer Hospital & Institute
NaSingle-groupOpen-labelTreatment

Summary

The incidence of Melanoma is rapidly growthing,and in China,dacarbazine combined with cisplatin is conmendly used as the first-line chemotherapy of metastatic melanoma. But the response rate and survival results are very limited.This trial aim to add a safe and effective anti-angiogenesis drug,Human-recombinant endostatin,to find out a new strategy which may further extend the PFS and OS with a tolerated toxicity.

Timeline

Start
2016-10
Primary completion
2017-12
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 15 mg/m2 Intravenous

Indications